“Smoldering multiple myeloma” (SMM) is a blood and bone marrow disorder which can lead to multiple myeloma, a deadly cancer. Detecting the condition can be a challenge, because those living with SMM ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active ...
Early interventions with daratumumab reduced progression and prolonged overall survival rate in patients with high-risk ...
Hosted on MSN28d
Treatment of Smoldering Myeloma Cuts Progression Rate in HalfSAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex ...
Darzalex Faspro improved PFS and OS in high-risk smoldering multiple myeloma, reducing progression or death risk by 51% and death risk by 48%. The AQUILA study showed a superior overall response rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback